PROFILUL METABOLIC AL PACIENTULUI CU LITIAZÃ BILIARÃ COLESTEROLICÃ

  • Clementina COJOCARU Universitatea de Medicină și Farmacie ”Gr. T. Popa” Iași
  • G. I. PANDELE Universitatea de Medicină și Farmacie ”Gr. T. Popa” Iași
Keywords: INSULIN RESISTANCE, METABOLIC SYNDROME, CHOLESTEROL GALLSTONES

Abstract

Metabolic syndrome is a clustering of cardiovascular risk factors as well as
associated co morbidities, including cholesterol gallstones disease.The aim of our study is to
prove the association between metabolic syndrome and cholesterol gallstones, to identify the
main risk factors for this association and to trace the particularities of the metabolic syndrome
in such patients. Material and method: Our cohort study enrolled 449 subjects, 312 patients
diagnosed with metabolic syndrome and gallstones or cholecystectomy (group 1) and 137
patients diagnosed only with metabolic syndrome (group 2), hospitalized in the Respiratory
Rehabilitation Medical Clinic between 2007-2009. Results: 85.25% of the patients with
metabolic syndrome and cholesterol gallstones and 79.92% of the patients with metabolic
syndrome alone had a body mass index (BMI) ³ 25 Kg/m2. Univariate and multivariate logistic
regression were used to calculate the risk of gallstone disease associated with different
metabolic syndrome variables. Waist circumference, BMI, fasting glycemia, insulinemia and
insulin resistance index (HOMA-IR) registered statistical significant differences between the
two study groups and were significantly associated with a higher risk of cholesterol gallstone as
well as were blood pressure values ³130/85 mmHg. The presence of 4 or 5 components of the
metabolic syndrome increased the risk of gallstone disease by 3 times (OR = 3.3, p<0.001)
compared to a 2 times higher risk (OR=2.1, p=0.02) in case of increased insulin resistance;
there was no statistical significance for any of the lipid parameters. Conclusion: In our study,
cholesterol gallstones appeared strongly associated with anthropometric measurements, fasting
glycemia and insulin resistance index, as well as with the presence of metabolic syndrome as
defined by the new clinical definition, despite the negative results for the lipidic components.
These findings are consistent with the hypothesis that insulin resistance plays an important role
in the pathogenesis and that cholesterol gallstone disease belong to metabolic syndrome.

Author Biographies

Clementina COJOCARU, Universitatea de Medicină și Farmacie ”Gr. T. Popa” Iași

Facultatea de Medicinã
Disciplina de Semiologie Medicalã
Spitalul Clinic de Recuperare Iași
Secția Clinicã Medicalã - Recuperare Respiratorie

G. I. PANDELE, Universitatea de Medicină și Farmacie ”Gr. T. Popa” Iași

Facultatea de Medicinã
Disciplina de Semiologie Medicalã

References

1. Reaven GM. Banting lecture 1988. Role of insulin resistance in human disease. Diabetes 1988;
37: 1595-1607.
2. Grundy SM. Metabolic Syndrome: A Multiplex Cardiovascular Risk Factor. J Clin Endocrinol Metab
2007; 92: 399–404.
3. Grundy SM. Cholesterol Gallstones: a fellow traveler with metabolic syndrome ? Am J Clin Nutr
2004; 80: 1-2.
4. Alberti KG, Eckel RH, Grundy SM et al. Harmonizing the metabolic syndrome. A joint interim statement of
the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung,
and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis
Society; and International Association for the Study of Obesity. Circulation 2009; 120: 1640-1645.
5. Attili AF, Capoccacia R, Carulli N et al. Factors associated with gallstone disease in the MICOL
experience. Hepatol 1997; 26: 809-818.
6. Ruhl CE, Everhart JE. Relationship of serum leptin concentration and other measures of adiposity
with gallbladder disease. Hepatol 2001; 34: 877-883.
7. Tsai C-J, Leitzmann MF, Willett WC, Giovannucci EL. Prospective study of abdominal adiposity
and gallstone disease in US men. Am J Clin Nutr 2004; 80: 38–44.
8. Duran-Sandoval D, Carion B, Fruchart JC, Staels B. Potential regulatory role of the farnesoid X
receptor in the metabolic syndrome. Biochimie 2005; 87: 93-98.
9. Acalovschi Monica. Litiaza biliarã colesterolic㠖 de la epidemiologie la geneticã. Cluj: Ed.
Clusium, 2008.
10. Kahn HS. The “lipid accumulation product” performs better than the body mass index for recognizing
cardiovascular risk: a population-based comparison. BMC Cardiovascular Disorders 2005; 5: 26-31.
11. Acalovschi M, Blendea D, Pascu M et al. Risk of asymptomatic and symptomatic gallstones in
moderately obese women: a longitudinal follow-up. Am J Gastroenterol 1997; 92: 127-131.
12. Thijs C, Knipschild P, Brombacher P. Serum lipids and gallstones: a case-control study.
Gastroenterol 1990; 99: 843-849.
13. Park YW, Zhu S, Palaniappan L, Heshka S, Carnethon MR, Heymsfield SB. The metabolic syndrome:
Prevalence and associated risk factor findings in the US population from the Third National Health and
Nutrition Examination Survey, 1988-1994. Arch Intern Med 2003; 163: 427-436.
Published
2019-04-19
Section
INTERNAL MEDICINE - PEDIATRICS